Home » Stocks » AnaptysBio

AnaptysBio, Inc. (ANAB)

Stock Price: $27.93 USD 0.20 (0.72%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
After-hours: $27.00 -0.93 (-3.33%) Oct 27, 6:01 PM

Stock Price Chart

Key Info

Market Cap 762.59M
Revenue (ttm) 18.00M
Net Income (ttm) -81.11M
Shares Out 27.30M
EPS (ttm) -2.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $27.93
Previous Close $27.73
Change ($) 0.20
Change (%) 0.72%
Day's Open 28.75
Day's Range 27.50 - 30.52
Day's Volume 838,464
52-Week Range 10.00 - 39.48

More Stats

Market Cap 762.59M
Enterprise Value 384.65M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 27.30M
Float 24.84M
EPS (basic) -2.99
EPS (diluted) -2.99
FCF / Share -2.68
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.30M
Short Ratio 12.96
Short % of Float 17.32%
Beta 0.79
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 42.37
PB Ratio 1.86
Revenue 18.00M
Operating Income -88.89M
Net Income -81.11M
Free Cash Flow -73.18M
Net Cash 377.94M
Net Cash / Share 13.84
Gross Margin -507.43%
Operating Margin -493.84%
Profit Margin -450.60%
FCF Margin -406.54%
ROA -12.60%
ROE -19.55%
ROIC -37.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (6)

Buy 2
Overweight 0
Hold 3
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

(-1.54% downside)
Current: $27.93
Target: 27.50
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth60%-50%-40.06%-5.05%10.94%-
Gross Profit8.005.0010.0016.6817.5715.84
Operating Income-107-66.72-28.78-3.03-3.324.87
Net Income-97.34-61.66-30.07-4.26-5.413.53
Shares Outstanding27.0624.6719.782.642.552.48
Earnings Per Share-3.60-2.50-1.52-1.62-2.120.09
Operating Cash Flow-69.52-48.51-19.44-9.03-9.6914.60
Capital Expenditures-0.81-1.06-0.29-0.05-0.24-0.14
Free Cash Flow-70.32-49.57-19.73-9.08-9.9314.46
Cash & Equivalents37442724851.2951.74-
Total Debt1.387.5714.4313.814.90-
Net Cash / Debt37342023437.4846.84-
Book Value405486308-38.25-35.18-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name AnaptysBio, Inc.
Country United States
Employees 89
CEO Hamza Suria

Stock Information

Ticker Symbol ANAB
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ANAB
IPO Date January 26, 2017


AnaptysBio, a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis and palmoplantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd.; and collaboration with Celgene Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.